Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer

被引：0
|
作者：
Hiroshi Yokouchi
Koichi Yamazaki
Ichiro Kinoshita
Jun Konishi
Hajime Asahina
Noriaki Sukoh
Masao Harada
Kenji Akie
Shigeaki Ogura
Takashi Ishida
Mitsuru Munakata
Hirotoshi Dosaka-Akita
Hiroshi Isobe
Masaharu Nishimura
机构：
[1] Hokkaido University School of Medicine,First Department of Medicine
[2] Hokkaido University Graduate School of Medicine,Department of Medical Oncology
[3] National Hospital Organization Hokkaido Cancer Center,Department of Respiratory Medicine
[4] Sapporo City General Hospital,Department of Respiratory Disease
[5] Fukushima Medical University,Department of Pulmonary Medicine
[6] KKR Sapporo Medical Center,Department of Medical Oncology
[7] Hokkaido Lung Cancer Clinical Research Group,undefined
来源：
BMC Cancer | / 7卷
关键词：
Overall Survival; Epidermal Growth Factor Receptor; Bone Metastasis; Gefitinib; Epidermal Growth Factor Receptor Gene;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Response to gefitinib and erlotinib in Non-small cell lung cancer: a retrospective study
    Ivette F Emery
    Chiara Battelli
    Paul L Auclair
    Kathleen Carrier
    Daniel M Hayes
    BMC Cancer, 9
  • [42] Antiproliferative Effects of Combined Tamoxifen and Gefitinib in Non-Small Cell Lung Cancer
    Hua Shen
    Yuan Yuan
    Wen Gao
    Jin Sun
    Shu, Yong-qian
    BIOMEDICINE & PHARMACOTHERAPY, 2009, 63 (05) : 327 - 327
  • [43] The role of gefitinib in the management of Asian patients with non-small cell lung cancer
    Chang, Alex Y.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2008, 17 (03) : 401 - 411
  • [44] Recurrence patterns of advanced non-small cell lung cancer treated with gefitinib
    CHEN Min-jiang
    ZHONG Wei
    ZHANG Li
    ZHAO Jing
    LI Long-yun
    WANG Meng-zhao
    中华医学杂志（英文版）, 2013, 126 (12) : 2235 - 2241
  • [45] Effectiveness and cost of gefitinib in advanced/metastatic non-small cell lung cancer
    Selvi-Sabater, P.
    Sanchez-Martinez, I.
    Sadyrbaeva-Dolgova, S.
    Portillo-Haro, S.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2020, 42 (01) : 289 - 289
  • [46] Inhibiting proliferation of gefitinib-resistant, non-small cell lung cancer
    Sudo, Makoto
    Chin, Tan Min
    Mori, Seiichi
    Doan, Ngan B.
    Said, Jonathan W.
    Akashi, Makoto
    Koeffler, H. Phillip
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (05) : 1325 - 1334
  • [47] Comparison Of Icotinib, Erlotinib And Gefitinib in Treating Non-Small Cell Lung Cancer
    Si, X.
    Wang, H.
    Zhang, X.
    Wang, M.
    Zhang, L.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [48] Recurrence patterns of advanced non-small cell lung cancer treated with gefitinib
    Chen Min-jiang
    Zhong Wei
    Zhang Li
    Zhao Jing
    Li Long-yun
    Wang Meng-zhao
    CHINESE MEDICAL JOURNAL, 2013, 126 (12) : 2235 - 2241
  • [49] Response to gefitinib and erlotinib in Non-small cell lung cancer: a retrospective study
    Emery, Ivette F.
    Battelli, Chiara
    Auclair, Paul L.
    Carrier, Kathleen
    Hayes, Daniel M.
    BMC CANCER, 2009, 9 : 333
  • [50] Inhibiting proliferation of gefitinib-resistant, non-small cell lung cancer
    Makoto Sudo
    Tan Min Chin
    Seiichi Mori
    Ngan B. Doan
    Jonathan W. Said
    Makoto Akashi
    H. Phillip Koeffler
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 1325 - 1334
12345